Assessing the clinical benefit from medical therapies in CNS malignancies: Refining the ESMO Magnitude of Clinical Benefit Scale and the ASCO Value Framework
The Neuro-MCBS is a comprehensive, clinically relevant tool and particularly suitable to assess the clinical benefit derived from novel antitumor therapies in neuro-oncology studies.
Authors
- Mirjam Renovanz (ORCID: https://orcid.org/0000-0002-2824-3720)
- Michael Bitzer
- Marcos Soares Tatagiba (ORCID: https://orcid.org/0000-0002-1627-9937)
- Nisar P. Malek (ORCID: https://orcid.org/0000-0002-9916-4608)
- Maximilian Niyazi (ORCID: https://orcid.org/0000-0002-7711-9486)
- Sylvia Christine Kurz (ORCID: https://orcid.org/0000-0002-5247-5636)
- Ghazaleh Tabatabai (ORCID: https://orcid.org/0000-0002-3542-8782)
Institutions
- University Children's Hospital Tübingen (DE)
- Bernstein Center for Computational Neuroscience Tübingen (DE)
- Hertie Institute for Clinical Brain Research (DE)
- University of Tübingen (DE)
Publication Details
- Journal
- Neuro-Oncology Advances
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1093/noajnl/vdaf127
- Citations
- 1
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63